The pathogenesis of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and
other forms of interstitial lung disease, involves a complex interplay of various factors …

Objective To review the available evidence on the impact of rheumatoid arthritis (RA)
treatments in associated diffuse interstitial lung disease (ILD). Methods Systematic review of …

Interstitial lung disease (ILD) is a challenging clinical entity associated with multiple
connective tissue diseases, and is a significant cause of morbidity and mortality. Effective …

Objective Interstitial lung disease (ILD) is a common manifestation of connective tissue
disease (CTD) that manifests as several subtypes with significant differences in prognosis. It …

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) mainly
encountered in patients with diffuse disease. Unlike idiopathic interstitial pneumonias (IIP) …

Fibrotic interstitial lung diseases (ILDs) frequently have nonspecific and overlapping clinical
and radiological features, resulting in∼ 10–20% of patients with ILD lacking a clear …

A systematic approach is recommended to search for clinical and biological features of
connective tissue disease (CTD) in any patient with interstitial lung disease (ILD). In the …

Interstitial lung disease is common in the rheumatic diseases, may be caused by a variety of
lesions that respond differently to treatment, and may lead to the development of pulmonary …

Background and objective In patients with severe interstitial lung disease (ILD) progressing
despite conventional immunosuppression, rituximab, a B‐lymphocyte depleting monoclonal …

Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at
increased risk of developing lung cancer. Management of lung cancer in patients with ILD is …